Krystal Biotech

Krystal Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The firm developed a proprietary gene delivery platform that enables off-the-shelf treatments for serious rare diseases with significant unmet need, initially in the areas of dermatology and respiratory diseases. Its platform consists of a patented, engineered viral vector derived from the herpes simplex virus type 1 that is optimized for local and repeat gene transfer to epithelial cells, and initially using its platform to develop treatments for rare or orphan monogenic diseases caused by the absence of or a mutation in a single gene. It is also involved in leveraging its platform to develop novel therapies to treat more prevalent conditions, and also focuses on developing treatments for use in the setting of aesthetic skin conditions. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Krystal Biotech reports robust Q3 earnings and eyes global expansion

Krystal Biotech's Q3 performance showcased positive earnings and high patient conversion rates.
Despite challenges in patient source diversity and conversion cycle, the company remains well-positioned.
Opportunities lie in global expansion, pipeline advancement, and leadership enhancements.
Overall, Krystal Biotech's strong financials and patient compliance bode well for future growth.

Krystal Biotech excels with VYJUVEK, eyes global expansion

Krystal Biotech's VYJUVEK shows strong performance and market potential
Balanced financials and strategic clinical trials position for future growth
Challenges include competitive landscape shifts and global expansion execution
Opportunities lie in market expansion, pipeline advancements, and partnerships

Krystal Biotech excels in Q1 2024, eyes global expansion

Krystal Biotech's strong performance in Q1 2024 reflects continued growth and execution.
The company's focus on compliance, pipeline advancements, and global expansion positions it well.
Challenges in conversion time and reimbursement delays require strategic mitigation.
Opportunities in European and Japanese markets, patient education, and new product data.

Krystal Biotech excels in Q2 2024, eyes global expansion

Krystal Biotech's Q2 2024 performance reflects strong revenue growth, profitability, and operational efficiency, positioning the company well for future success.
The company's focus on patient demand, compliance, and global expansion highlights its strategic priorities and growth trajectory.
While facing challenges in manufacturing expansion and clinical data readouts, Krystal Biotech has opportunities to drive revenue growth and market expansion through strategic initiatives.

Krystal Biotech excels in Q3 with VYJUVEK success and global expansion plans

Krystal Biotech's Q3 performance reflects strong revenue growth, profitability, and strategic advancements in product development and market access.
While facing challenges related to compliance, market dynamics, and competitive landscape, the company is well-positioned for international expansion and future growth.
By capitalizing on strengths in commercial strategies, pipeline progress, and revenue diversification, Krystal Biotech can navigate challenges and seize opportunities for sustained success.

Krystal Biotech excels in 2024 with strong revenue growth and global expansion plans

Krystal Biotech's Q4 2024 Earnings Call showcased a thriving business with strong financial performance, successful product launches, and strategic plans for future growth amidst industry challenges and opportunities.

Krystal Biotech reports robust Q1 earnings, eyes global expansion

Krystal Biotech's Q1 2025 showcased strong financial performance, highlighting revenue growth and positive patient impact stories. The company faces challenges in patient pausing post-induction and increased expenses but has opportunities in upcoming clinical milestones and global expansion.

Krystal Biotech excels in Q2 with VYJUVEK success and global expansion

Krystal Biotech's Q2 performance reflects strong revenue generation and financial stability, driven by the success of VYJUVEK and ongoing R&D efforts. The company's patient-centric approach, focus on innovation, and global expansion strategies position it well for future growth and market leadership. While facing challenges in operational metrics and balancing profitability with investments, Krystal Biotech has opportunities to capitalize on market potential and drive revenue growth.

Krystal Biotech excels in Q3 with VYJUVEK launch and global expansion

Krystal Biotech's Q3 2025 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts. The company's focus on pipeline advancements and global expansion positions it well for future growth and market leadership. While challenges like optimizing manufacturing processes and addressing safety observations exist, opportunities in new markets and pipeline programs offer avenues for continued success.

Krystal Biotech excels in Q4 revenue, eyes global expansion

Krystal Biotech's Q4 2025 earnings call highlighted strong revenue performance, successful global expansion, and promising pipeline developments. The company faces challenges in pricing negotiations, patient compliance, and new market launches, but opportunities exist in further U.S. growth, stock buybacks, and R&D advancements. Overall, Krystal Biotech's focus on commercial excellence, geographic expansion, and innovation positions it well for future growth and market leadership.

Krystal Biotech's Q1 2026 earnings call highlighted strong financial performance, international progress, and strategic advancements in platform technologies. The company faces challenges in commercial strategies and market dynamics but has opportunities for growth through upcoming studies and market expansions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Krystal Biotech, Inc. operates as a biotechnology company, which engages in discovery, development, manufacturing, and commercialization of pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.